Clinical trials: China
Multiple Myeloma
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.
- Trial name
- NCT03748953
- Testing
- Ixazomib
- Where
- 10 sites in China
- Volunteers
- 37 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and sitagliptin (a medicine doctors can already prescribe).
- Trial name
- PIONEER 12 (NCT04017832)
- Testing
- Oral semaglutide, Sitagliptin
- Where
- 93 sites in Algeria, Brazil and 7 more
- Volunteers
- 1,441 people
- Sponsor
- Novo Nordisk A/S
Poliomyelitis
Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers
This study aims to evaluate the persistence of anti-poliovirus antibodies in toddlers aged 18 months who were primed with oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in the primary study.
- Trial name
- NCT01323647
- Testing
- PoliorixTM, Infanrix+Hib
- Where
- 2 sites in China
- Volunteers
- 957 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no…
- Trial name
- LEAP-007 (NCT04676412)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 17 sites in China
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
HBV, Chronic HBV Infection
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT02836249
- Testing
- TAF, TDF
- Where
- 25 sites in China
- Volunteers
- 181 people
- Sponsor
- Gilead Sciences
Lateral Canthal Lines, Crow's Feet Lines
BOTOX® in the Treatment of Crow's Feet Lines in China
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).
- Trial name
- NCT02195687
- Testing
- botulinum toxin Type A, Normal Saline
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Allergan
Valvular Heart Disease, Aortic Valve Disease
Regent China Post-Market Clinical Follow-up Study
Regent China Post-Market Clinical Follow-Up (RC-PMCF): this clinical study is to confirm the safety and performance of Abbott's Regent MHV for replacement of native or prosthetic aortic valves in a Chinese population.
- Trial name
- NCT05330468
- Testing
- Abbott Mechanical Heart Valve (MHV) Regent™
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices
Type 2 Diabetes Mellitus
Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China
This is a multi-centre, cross-sectional, non-interventional study assessing blood glucose target attainment, anti-hyperglycaemic treatment pattern and the clinical characteristics in older outpatients with Type 2 Diabetes…
- Trial name
- NCT03064841
- Testing
- No Treatment
- Where
- 18 sites in China
- Volunteers
- 1,537 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)
This study will assess the efficacy and safety of initial treatment with sitagliptin and metformin in patients with type 2 diabetes mellitus in China.
- Trial name
- NCT01076088
- Testing
- Sitagliptin 50 mg, Metformin 500 mg, Sitagliptin 100 mg
- Volunteers
- 744 people
- Sponsor
- Merck Sharp & Dohme LLC
Erectile Dysfunction
A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China
The primary objective of this study is to evaluate whether, after two 8-week treatment periods, male patients with erectile dysfunction (ED) in China prefer 20 milligram (mg) tadalafil or 100 mg sildenafil.
- Trial name
- NCT01352507
- Testing
- Tadalafil, Sildenafil
- Where
- 9 sites in China
- Volunteers
- 383 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable insulin alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01590797
- Testing
- Sitagliptin, Insulin, Metformin
- Volunteers
- 467 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study
In this China extension study, carboplatin and paclitaxel with or without pembrolizumab (MK-3475, KEYTRUDA®) will be administered to Chinese adults with first line metastatic squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT03875092
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Merck Sharp & Dohme LLC
Hydrocephalus
Bactiseal Catheter Safety Registry in China
Research Purpose: This study aimed to continue to evaluate safety information from subjects implanted with a catheter (trade name: Bactiseal) produced by Codman \& Shurtleff, Inc. of the United States.
- Trial name
- NCT04496414
- Testing
- Bactiseal Catheter
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Integra LifeSciences Corporation
Type 2 Diabetes Mellitus
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Chinese Subjects in China with Type 2 Diabetes…
- Trial name
- NCT02104804
- Testing
- Saxagliptin 5mg
- Where
- 11 sites in China
- Volunteers
- 953 people
- Sponsor
- AstraZeneca
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
In the China extension study, Chinese participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that has progressed…
- Trial name
- NCT03933449
- Testing
- pembrolizumab, paclitaxel, docetaxel
- Where
- 23 sites in China
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed and Refractory Multiple Myeloma
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.
- Trial name
- NCT03029234
- Testing
- Dexamethasone, Carfilzomib
- Where
- 17 sites in China
- Volunteers
- 126 people
- Sponsor
- Amgen
Alzheimer's Disease
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
- Trial name
- STDMMAD (NCT02787746)
- Testing
- Donepezil
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Beijing Friendship Hospital
Liver Failure, Acute on Chronic
Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Acute on chronic liver failure (ACLF) is a distinct entity encompassing the acute deterioration of liver function, culminating in multiple organs failure and high short-term mortality.
- Trial name
- Ch-CANONIC (NCT02457637)
- Testing
- Standary therapy
- Where
- 16 sites in China
- Volunteers
- 2,600 people
- Sponsor
- Hai Li
Healthy
A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®
This is a 12-week, randomized, double-blind, single-dose pharmacokinetic (PK) study. Approximately 114 healthy male participants (screening occurred within 28 days prior to dosing) will be randomized 1:1:1 to either TRS003…
- Trial name
- NCT03882424
- Testing
- TRS003, China-approved Bevacizumab, US-licensed Avastin
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
Multiple Myeloma
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Chinese participants with…
- Trial name
- DREAMM 7 (NCT06868654)
- Testing
- Belantamab mafodotin, Daratumumab, Bortezomib
- Where
- 11 sites in China
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline